Shares of Theravance Biopharma Inc. (NASDAQ:TBPH) were down 0.5% during mid-day trading on Friday . The company traded as low as $28.57 and last traded at $28.71, with a volume of 70,302 shares changing hands. The stock had previously closed at $28.86.

A number of analysts recently issued reports on TBPH shares. Bank of America Corp. cut Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 3rd. Leerink Swann upped their target price on Theravance Biopharma to $29.00 and gave the company an “outperform” rating in a research report on Monday, June 20th. Zacks Investment Research cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Evercore ISI initiated coverage on Theravance Biopharma in a research report on Monday, August 29th. They set a “buy” rating and a $41.00 price objective for the company. Finally, Guggenheim initiated coverage on Theravance Biopharma in a research report on Monday, June 20th. They set a “buy” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $32.00.

The firm has a 50 day moving average price of $25.93 and a 200-day moving average price of $21.73. The company’s market capitalization is $1.38 billion.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.01. Equities analysts predict that Theravance Biopharma Inc. will post ($4.03) earnings per share for the current fiscal year.

In other news, SVP Brett K. Haumann sold 4,491 shares of Theravance Biopharma stock in a transaction dated Thursday, August 25th. The stock was sold at an average price of $27.99, for a total transaction of $125,703.09. Following the sale, the senior vice president now directly owns 188,293 shares of the company’s stock, valued at $5,270,321.07. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Bradford J. Shafer sold 49,122 shares of Theravance Biopharma stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $27.46, for a total value of $1,348,890.12. Following the sale, the executive vice president now directly owns 241,686 shares in the company, valued at $6,636,697.56. The disclosure for this sale can be found here.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.